Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating female 12 years of age or older with a minimum of 2 years of previous history of seasonal allergic rhinitis to the pollen/allergen in season at the time the study is being conducted.~* Signed informed consent (assent) form.~* Documented positive allergic skin test to local pollen.~* An average score of at least 6 on the reflective Total Nasal Symptom Score (rTNSS) with a minimum score of at least 2 for nasal congestion and at least 4 on the reflective Total Ocular Symptom Score (rTOSS).~Exclusion Criteria:~* History of asthma that required chronic therapy (with the exception of occasional acute or mild exercise induced asthma).~* Some other past and concomitant medical conditions, prohibited medications.~* Upper respiratory tract infection or any untreated infections.~* Patient has started immunotherapy/changed the dose.~* Any known allergy to any of the components of the study nasal spray.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test (Type: EXPERIMENTAL): Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals) administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
- Reference (Type: ACTIVE_COMPARATOR): Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo nasal spray administered once daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).